
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience Inc's portfolio includes promising clinical-stage assets such as ALTO-207, which has shown significant improvements in patient outcomes during clinical trials, including favorable safety profiles and enhanced cognitive performance. Additionally, ALTO-300 aims to reduce liver toxicity while improving pharmacokinetics, showcasing the company's commitment to optimizing existing therapies for better efficacy. The acquisition of ALTO-207, which leverages established treatments and exhibits strong therapeutic effects, has further heightened investor interest and optimism surrounding the company's innovative approach to psychiatry.
Bears say
Alto Neuroscience faces significant challenges that contribute to a negative outlook on its stock, primarily derived from the high failure rates associated with clinical trials in depression, exacerbated by issues such as patient heterogeneity and high placebo response. Moreover, the company's reliance on critical patents for asset protection introduces additional risk; the potential non-issuance or dispute of these patents could lead to diminished market viability and a subsequent decrease in valuation. Lastly, noted adverse effects from study drugs, including nausea, dizziness, and lightheadedness, further complicate the development landscape and may undermine patient compliance and treatment efficacy.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares